Jump to Navigation
Banner

Overview

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to address HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians.

 

Recent News
May 24, 2017

Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced James Joyce, CEO, will be a featured presenter at the...

Apr 24, 2017

Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following shareholder update authored by its Chairman and CEO, Jim Joyce. Dear Shareholders, I first want to express my appreciation for...

View all News Releases

Events

print email

Back to Top


Site 'Subpage' Navigation:

Investor Relations

NASDAQAEMD
Investor Contact

Aethlon Medical, Inc.
858-459-7800

Back to Top